+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Dysmenorrhea Treatment Market Research Report by Type, Treatment, Diagnosis, Mode of Prescription, Route of Administration, End-Users, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

  • PDF Icon

    Report

  • 134 Pages
  • January 2023
  • Region: United States
  • 360iResearch™
  • ID: 5721712
The United States Dysmenorrhea Treatment Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation. Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Dysmenorrhea Treatment Market.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States Dysmenorrhea Treatment Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States Dysmenorrhea Treatment Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States Dysmenorrhea Treatment Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States Dysmenorrhea Treatment Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States Dysmenorrhea Treatment Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type, the market is studied across Primary Dysmenorrhea and Secondary Dysmenorrhea.
  • Based on Treatment, the market is studied across Medication, Surgery, and Therapy.
  • Based on Diagnosis, the market is studied across CT Scan, Laparoscopy, Magnetic Resonance Imaging, and Ultrasound.
  • Based on Mode of Prescription, the market is studied across Over the Counter and Prescription.
  • Based on Route of Administration, the market is studied across Implants, Oral, and Parenteral.
  • Based on End-Users, the market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States Dysmenorrhea Treatment Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States Dysmenorrhea Treatment Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States Dysmenorrhea Treatment Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States Dysmenorrhea Treatment Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Dysmenorrhea Treatment Market, including Abbott Laboratories, Alvogen, Bayer AG, Cora Life, F. Hoffmann-La Roche Ltd., Focus Consumer Healthcare, GlaxoSmithKline PLC, Merck KGaA, Novartis AG, Nua, Pfizer Inc., Reckitt Benckiser Group PLC, Sanofi, Taj Pharmaceuticals Limited, and Vanita's Rehab.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Dysmenorrhea Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Dysmenorrhea Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Dysmenorrhea Treatment Market?
4. What is the competitive strategic window for opportunities in the United States Dysmenorrhea Treatment Market?
5. What are the technology trends and regulatory frameworks in the United States Dysmenorrhea Treatment Market?
6. What is the market share of the leading vendors in the United States Dysmenorrhea Treatment Market?
7. What modes and strategic moves are considered suitable for entering the United States Dysmenorrhea Treatment Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of dysmenorrhea among adolescent girls and geriatric population
5.1.1.2. U.S. government measures to raise awareness
5.1.2. Restraints
5.1.2.1. Side effects and complications with dysmenorrhea treatment
5.1.3. Opportunities
5.1.3.1. Innovations and research activities for the management of dysmenorrhea
5.1.4. Challenges
5.1.4.1. Reluctance of dysmenorrhea patients to seek treatment
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Dysmenorrhea Treatment Market, by Type
6.1. Introduction
6.2. Primary Dysmenorrhea
6.3. Secondary Dysmenorrhea

7. Dysmenorrhea Treatment Market, by Treatment
7.1. Introduction
7.2. Medication
7.3. Surgery
7.4. Therapy

8. Dysmenorrhea Treatment Market, by Diagnosis
8.1. Introduction
8.2. CT Scan
8.3. Laparoscopy
8.4. Magnetic Resonance Imaging
8.5. Ultrasound

9. Dysmenorrhea Treatment Market, by Mode of Prescription
9.1. Introduction
9.2. Over the Counter
9.3. Prescription

10. Dysmenorrhea Treatment Market, by Route of Administration
10.1. Introduction
10.2. Implants
10.3. Oral
10.4. Parenteral

11. Dysmenorrhea Treatment Market, by End-Users
11.1. Introduction
11.2. Homecare
11.3. Hospitals
11.4. Specialty Clinics

12. California Dysmenorrhea Treatment Market
12.1. Introduction

13. Florida Dysmenorrhea Treatment Market
13.1. Introduction

14. Illinois Dysmenorrhea Treatment Market
14.1. Introduction

15. New York Dysmenorrhea Treatment Market
15.1. Introduction

16. Ohio Dysmenorrhea Treatment Market
16.1. Introduction

17. Pennsylvania Dysmenorrhea Treatment Market
17.1. Introduction

18. Texas Dysmenorrhea Treatment Market
18.1. Introduction

19. Competitive Landscape
19.1. FPNV Positioning Matrix
19.1.1. Quadrants
19.1.2. Business Strategy
19.1.3. Product Satisfaction
19.2. Market Ranking Analysis, By Key Player
19.3. Market Share Analysis, By Key Player
19.4. Product Portfolio Analysis, By Key Player
19.5. Competitive Scenario
19.5.1. Merger & Acquisition
19.5.2. Agreement, Collaboration, & Partnership
19.5.3. New Product Launch & Enhancement
19.5.4. Investment & Funding
19.5.5. Award, Recognition, & Expansion

20. Company Usability Profiles
20.1. Abbott Laboratories
20.2. Alvogen
20.3. Bayer AG
20.4. Cora Life
20.5. F. Hoffmann-La Roche Ltd.
20.6. Focus Consumer Healthcare
20.7. GlaxoSmithKline PLC
20.8. Merck KGaA
20.9. Novartis AG
20.10. Nua
20.11. Pfizer Inc.
20.12. Reckitt Benckiser Group PLC
20.13. Sanofi
20.14. Taj Pharmaceuticals Limited
20.15. Vanita's Rehab

21. Appendix
21.1. Discussion Guide
21.2. License & Pricing

List of Figures
FIGURE 1. UNITED STATES DYSMENORRHEA TREATMENT MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. UNITED STATES DYSMENORRHEA TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES DYSMENORRHEA TREATMENT MARKET DYNAMICS
FIGURE 8. UNITED STATES DYSMENORRHEA TREATMENT MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES DYSMENORRHEA TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY TYPE, 2030
FIGURE 12. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY PRIMARY DYSMENORRHEA, 2018-2030 (USD MILLION)
FIGURE 13. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SECONDARY DYSMENORRHEA, 2018-2030 (USD MILLION)
FIGURE 14. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2022 VS 2030 (%)
FIGURE 15. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES DYSMENORRHEA TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY TREATMENT, 2030
FIGURE 17. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
FIGURE 18. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
FIGURE 19. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
FIGURE 20. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2022 VS 2030 (%)
FIGURE 21. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES DYSMENORRHEA TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY DIAGNOSIS, 2030
FIGURE 23. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY CT SCAN, 2018-2030 (USD MILLION)
FIGURE 24. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY LAPAROSCOPY, 2018-2030 (USD MILLION)
FIGURE 25. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING , 2018-2030 (USD MILLION)
FIGURE 26. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
FIGURE 27. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MODE OF PRESCRIPTION, 2022 VS 2030 (%)
FIGURE 28. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MODE OF PRESCRIPTION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 29. UNITED STATES DYSMENORRHEA TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY MODE OF PRESCRIPTION, 2030
FIGURE 30. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY OVER THE COUNTER, 2018-2030 (USD MILLION)
FIGURE 31. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
FIGURE 32. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
FIGURE 33. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 34. UNITED STATES DYSMENORRHEA TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY ROUTE OF ADMINISTRATION, 2030
FIGURE 35. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY IMPLANTS, 2018-2030 (USD MILLION)
FIGURE 36. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
FIGURE 37. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
FIGURE 38. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2022 VS 2030 (%)
FIGURE 39. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 40. UNITED STATES DYSMENORRHEA TREATMENT MARKET COMPETITIVE STRATEGIC WINDOW, BY END-USERS, 2030
FIGURE 41. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
FIGURE 42. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
FIGURE 43. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
FIGURE 44. CALIFORNIA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 45. FLORIDA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 46. ILLINOIS DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 47. NEW YORK DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 48. OHIO DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 49. PENNSYLVANIA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 50. TEXAS DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 51. UNITED STATES DYSMENORRHEA TREATMENT MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 52. UNITED STATES DYSMENORRHEA TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 53. UNITED STATES DYSMENORRHEA TREATMENT MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. UNITED STATES DYSMENORRHEA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 5. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY PRIMARY DYSMENORRHEA, 2018-2030 (USD MILLION)
TABLE 7. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY PRIMARY DYSMENORRHEA, BY STATE, 2018-2030 (USD MILLION)
TABLE 8. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SECONDARY DYSMENORRHEA, 2018-2030 (USD MILLION)
TABLE 9. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SECONDARY DYSMENORRHEA, BY STATE, 2018-2030 (USD MILLION)
TABLE 10. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 11. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 12. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, BY STATE, 2018-2030 (USD MILLION)
TABLE 13. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 14. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, BY STATE, 2018-2030 (USD MILLION)
TABLE 15. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 16. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPY, BY STATE, 2018-2030 (USD MILLION)
TABLE 17. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 18. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY CT SCAN, 2018-2030 (USD MILLION)
TABLE 19. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY CT SCAN, BY STATE, 2018-2030 (USD MILLION)
TABLE 20. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY LAPAROSCOPY, 2018-2030 (USD MILLION)
TABLE 21. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY LAPAROSCOPY, BY STATE, 2018-2030 (USD MILLION)
TABLE 22. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING , 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING , BY STATE, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY ULTRASOUND, BY STATE, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MODE OF PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY OVER THE COUNTER, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY OVER THE COUNTER, BY STATE, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY PRESCRIPTION, BY STATE, 2018-2030 (USD MILLION)
TABLE 31. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY IMPLANTS, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY IMPLANTS, BY STATE, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY ORAL, BY STATE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY PARENTERAL, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY HOMECARE, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY HOMECARE, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITALS, BY STATE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY STATE, 2018-2030 (USD MILLION)
TABLE 45. CALIFORNIA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 46. CALIFORNIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. CALIFORNIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. CALIFORNIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 49. CALIFORNIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MODE OF PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 50. CALIFORNIA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. CALIFORNIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 52. FLORIDA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 53. FLORIDA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. FLORIDA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 55. FLORIDA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 56. FLORIDA DYSMENORRHEA TREATMENT MARKET SIZE, BY MODE OF PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 57. FLORIDA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. FLORIDA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 59. ILLINOIS DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 60. ILLINOIS DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 61. ILLINOIS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 62. ILLINOIS DYSMENORRHEA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 63. ILLINOIS DYSMENORRHEA TREATMENT MARKET SIZE, BY MODE OF PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 64. ILLINOIS DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. ILLINOIS DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 66. NEW YORK DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 67. NEW YORK DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. NEW YORK DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. NEW YORK DYSMENORRHEA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 70. NEW YORK DYSMENORRHEA TREATMENT MARKET SIZE, BY MODE OF PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 71. NEW YORK DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. NEW YORK DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 73. OHIO DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 74. OHIO DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 75. OHIO DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 76. OHIO DYSMENORRHEA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 77. OHIO DYSMENORRHEA TREATMENT MARKET SIZE, BY MODE OF PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 78. OHIO DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. OHIO DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 80. PENNSYLVANIA DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 81. PENNSYLVANIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. PENNSYLVANIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. PENNSYLVANIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 84. PENNSYLVANIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MODE OF PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 85. PENNSYLVANIA DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. PENNSYLVANIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 87. TEXAS DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 88. TEXAS DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. TEXAS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 90. TEXAS DYSMENORRHEA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 91. TEXAS DYSMENORRHEA TREATMENT MARKET SIZE, BY MODE OF PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 92. TEXAS DYSMENORRHEA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. TEXAS DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES DYSMENORRHEA TREATMENT MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 95. UNITED STATES DYSMENORRHEA TREATMENT MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 96. UNITED STATES DYSMENORRHEA TREATMENT MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 97. UNITED STATES DYSMENORRHEA TREATMENT MARKET RANKING, BY KEY PLAYER, 2022
TABLE 98. UNITED STATES DYSMENORRHEA TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
TABLE 99. UNITED STATES DYSMENORRHEA TREATMENT MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 100. UNITED STATES DYSMENORRHEA TREATMENT MARKET MERGER & ACQUISITION
TABLE 101. UNITED STATES DYSMENORRHEA TREATMENT MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 102. UNITED STATES DYSMENORRHEA TREATMENT MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 103. UNITED STATES DYSMENORRHEA TREATMENT MARKET INVESTMENT & FUNDING
TABLE 104. UNITED STATES DYSMENORRHEA TREATMENT MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 105. UNITED STATES DYSMENORRHEA TREATMENT MARKET: LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • Alvogen
  • Bayer AG
  • Cora Life
  • F. Hoffmann-La Roche Ltd.
  • Focus Consumer Healthcare
  • GlaxoSmithKline PLC
  • Merck KGaA
  • Novartis AG
  • Nua
  • Pfizer Inc.
  • Reckitt Benckiser Group PLC
  • Sanofi
  • Taj Pharmaceuticals Limited
  • Vanita's Rehab

Methodology

Loading
LOADING...